<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01315080</url>
  </required_header>
  <id_info>
    <org_study_id>FISTULA001</org_study_id>
    <nct_id>NCT01315080</nct_id>
  </id_info>
  <brief_title>Efficacy of Percutaneous Injection of Triamcinolone in the Treatment of Mammillary Fistula</brief_title>
  <official_title>Efficacy of Percutaneous Injection of Triamcinolone in the Treatment of Mammillary Fistula</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Virgen de la Arrixaca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Virgen de la Arrixaca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators recently proposed a new hypothesis on the pathogenesis of mammillary
      fistulae (MF) suggesting that occlusion of hair follicles by keratinous plugging may
      relevantly contribute to the development of MF. The investigators believe that the
      pathogenesis of MF mimics the behaviour of hidradenitis suppurative, as both clinical
      entities manifest themselves as a chronic, suppurative and recurrent inflammatory process.
      This new proposal has led to the present suggestion of a therapeutic alternative for MF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the results from a prospective observational database with two groups of patients:

        1. patients with MF treated by percutaneous drainage and saline solution.

        2. patients with MF treated by percutaneous drainage and saline solution plus percutaneous
           triamcinolone.

      These patients are treated following usual clinical practice in our Department. All the
      procedures are made through an ultrasound-guided way. During the follow-up of these cases
      (clinical and with ultrasound) resolution rate will be registered by the same investigator.

      The follow-up will be at least 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">March 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of mammillary fistula</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Mammillary Fistula</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <description>Percutaneous drainage and saline solution irrigation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triamcinolone</arm_group_label>
    <description>Percutaneous drainage and saline solution irrigation plus percutaneous triamcinolone</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with mammillary fistula
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mammillary fistula

          -  older than 18 years

          -  patient acceptation to the recruitment

        Exclusion Criteria:

          -  diabetes mellitus

          -  arterial hypertension

          -  immunodepression

          -  peptic ulcer

          -  chronic bowel inflammatory diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan D Berna, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virgen de la Arrixaca University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan D Berna, MD PhD</last_name>
    <phone>+34 968369500</phone>
    <phone_ext>29757</phone_ext>
    <email>jdberna@um.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Virgen de la Arrixaca University Hospital</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan D Berna, MD PhD</last_name>
      <phone>+34 968369500</phone>
      <phone_ext>29757</phone_ext>
      <email>jdberna@um.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2011</study_first_submitted>
  <study_first_submitted_qc>March 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2011</study_first_posted>
  <last_update_submitted>March 14, 2011</last_update_submitted>
  <last_update_submitted_qc>March 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Juan de Dios Berna Serna, MD PhD</name_title>
    <organization>Virgen de la Arrixaca University Hospital</organization>
  </responsible_party>
  <keyword>mammillary fistula</keyword>
  <keyword>triamcinolone</keyword>
  <keyword>ultrasound management</keyword>
  <keyword>percutaneous treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

